List of Small Molecule Pharmaceuticals Companies in Belgium - 21

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies.

Apaxen is a privately-held biotechnology company whose mission is to bring innovative treatments to patients in a wide range of therapeutic indications related to chronic inflammation, with a primary focus in pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases. The Company is specialized in the discovery and development of first-in-class small molecule inhibitors of pleiotropic pro-inflammatory cytokine “Macrophage migration Inhibitory Factor (MIF)”, a crucial regulator of innate immune responses. Apaxen’s lead compound, MFC-1040, an orally bioavailable and selective small molecule MIF inhibitor, is being developed for the treatment of pulmonary arterial hypertension (PAH), a rare and fatal disease, with a strong medical need since approved treatments are symptomatic and associated with low median survival. MFC-1040 has a unique mechanism of action and has the potential to revolutionize the standard of care of PAH and other diseases related to chronic inflammation. Apaxen has its headquarters in Gosselies, at the Biopark Charleroi Brussels South

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT), peripheral neuropathies and neurodegenerative disorders. The company is rooted in the ground-breaking research at VIB and KU Leuven and supported by Asabys Partners, Eli Lilly and Company, V-Bio Ventures, PMV, AdBio Partners, VIB, Gemma Frisius Fund and CMT Research Foundation. ——— *Disclaimer* ——— We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

BioLizard is a leading multi-national data analytics and data management consulting company supporting digital transformation in the life sciences industry by offering bespoke, tailored solutions. From data analytics and bioinformatics, to software development and AI, we support biopharma and biotech companies in accessing vital, data-driven insights that can be turned into actions and drive your life sciences research forward. Our team of experienced bioengineers, software engineers and computer science experts combines extensive data science expertise with deep biological knowledge to provide solutions that are tailored to your needs and in line with your unique strategic goals. We have a proven ability to support companies from discovery to pre- & early clinical phases, enabling data-driven R&D. Our expertise spans drug and biomarker discovery and development, in silico screening, target identification, development of companion diagnostics, mechanism-of-action studies, process automation, data strategy, and more. As your true data partner, we’re ready to help you leverage data to keep your competitive edge. Our expert ‘Lizards’ can support you no matter where you are in the world, and in a flexible, proactive, and agile way to drive your data-driven research forward. 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 𝗕𝗶𝗼𝗟𝗶𝘇𝗮𝗿𝗱 𝘁𝗼𝗱𝗮𝘆 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗮𝘁𝗮 𝗶𝗻𝘁𝗼 𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀. More information: https://lizard.bio/home Company video: https://www.youtube.com/watch?v=q9MR126aiNo&t=1s BioLizard careers: https://lizard.bio/careers

A biotech company dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies are robust and versatile protein scaffolds, unrelated to immunoglobulins, and inspired by naturally occurring motives. Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a broad range of intracellular disease related targets that are considered “intractable” by currently available drug formats, such as antibodies and small molecules.

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | www.etherna.be | www.ethernamanufacturing.com We are an RNA technology company, with over 30 years’ experience, offering professional partnership to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late stage projects by using our proprietary platforms across RNA chemistry, LNP formulation and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.

Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, who specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market. Eurogentec was founded in 1985. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. The life science BU specializes in Genomics (e.g. Lab scale to Large scale Oligonucleotides, PCR/qPCR Kits & Reagents and Assay Dispensing Service) and Proteomics (e.g. catalog and custom peptides & antibodies including a 28-Day Speedy protocol, assay kits and Proprietary Dyes & Quenchers). The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. The Biomanufacturing BU is a GMP Biomanufacturer specialized in the technology transfer, process development, scale-up and manufacturing of proteins, plasmids and vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements.

EyeD Pharma is a clinical-stage pharmaceutical company based in Belgium, founded in 2012. The company is dedicated to improving the lives of patients with ophthalmic diseases, focusing on innovative therapeutic solutions for conditions like glaucoma and dry eye. EyeD Pharma specializes in developing drug products for ophthalmology, particularly through sustained-release polymeric micro-implants and inserts. Their product pipeline includes TimoD, a small molecule drug targeting β-adrenoceptors, aimed at enhancing patient compliance and minimizing treatment side effects. The company employs around 68 people and is structured as a holding company. EyeD Pharma's mission is to become a leader in the development of ophthalmic sustained-release micro-implants and complex therapeutics, addressing significant medical needs in the field.

Formac Pharma is a pharmaceutical company that specializes in developing best in class new pharmaceutical products using silica-based drug delivery platforms to improve the performance of poorly soluble compounds, while also partnering with pharmaceutical and animal health companies.

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.a r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Huvepharma is a fast growing global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The company also manufactures and markets enzymes for food, feed and industrial applications. Huvepharma is a privately owned company headquartered in Sofia, Bulgaria.

ImmuneSpec offers a cutting-edge immunopeptidomics platform designed to accelerate and enhance the identification of immunogenic peptides. Utilizing a state-of-the-art mass spectrometry (MS)-based approach, our platform provides unparalleled accuracy and depth in profiling the peptide landscape presented by MHC molecules. By enabling the precise detection and characterization of these peptides, we empower life sciences, biotechnology companies, and CROs to accelerate the development of transformative therapies, including broad-spectrum vaccines, personalized medicine, and novel immunotherapeutics. By offering a thorough and unbiased analysis of the immunopeptidome, we empower researchers to discover new targets, enhance known antigens, and detect rare, mutation-derived neoepitopes that are ideal candidates for biotherapeutics. Additionally, we identify immunogenic regions within biotherapeutics, helping to optimize their design and reduce potential immunogenicity, thereby improving safety and efficacy profiles.

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

4Clinics is a Contract Research Organization (CRO) providing Data management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies with a particular expertise in vaccines, immunology, immuno-oncology and medical devices. 4Clinics serves pharmaceutical, biotechnology and medical devices companies as well as NGOs, hospitals and researchers with tailor-made services including remote biometry and medical writing platforms. 4Clinics has offices in Belgium, France and Morocco and has a global coverage. For more information, please visit www.4Clinics.com

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

Rejuvenate Biomed is a clinical-stage company dedicated to the discovery and development of therapeutics to prevent or delay the onset of multiple age-related diseases. Founded in 2017, Rejuvenate Biomed is a privately-held platform and pipeline company developing safe and proprietary combination drugs that help people healthy for life. By using platform technologies, Rejuvenate Biomed identifies safe compounds that influence the aging process. Novel combination drugs are discovered that have the potential to prevent or delay the onset of multiple age-related diseases. Rejuvenate Biomed confirms prediction data in preclinical models and in clinical studies. Rejuvenate Biomed’s lead drug candidate RJx-01 is currently in Phase 1b for the treatment of sarcopenia, the progressive age-associated loss of muscle function and mass.

Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuven’s Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. (Milano, Italy), a leading provider of integrated discovery services for the Life Sciences. Rewind Therapeutics works in close collaboration with both organisations and a world-class academic network to advance its discovery and development activities. Rewind Therapeutics is backed by life science investors Boehringer Ingelheim Venture Fund, M Ventures and the Flemish investment company PMV, together with CD3 and KU Leuven Gemma Frisius Fonds.

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2023 Key Financials: € 5.3 billion global revenue Specialties: Neurology, Immunology

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit.